Sun Pharma to acquire Checkpoint Therapeutics in oncology deal
Transaction to expand Sun Pharma’s onco-derm portfolio with FDA-approved treatment for advanced cSCC
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dilip Shanghvi
Sun Pharma amongst top 5% of global pharma companies in S&P Global Sustainability Yearbook 2025
Sun Pharma secures a spot in S&P Global’s Sustainability Yearbook 2025, reflecting its ESG commitments
No plans to enter vaccine production as it needs different manufacturing infra: Dilip Sanghvi
The company is eyeing biosimilars to fuel its future growth
IPA releases report titled, ‘Beyond Business: Contributions to Social Initiatives’
It examines the role played and impact created by IPA member companies through CSR
Aim to gain market share, preserve cash, reduce overall debt in times of COVID-19: Dilip Shanghvi
The company's focus is also on supply chain protection and ensuring optimum utilisation of its factories informed the MD of the…
Sun Pharma gets DCGI nod for clinical trial with Nafamostat in COVID-19 patients
Nafamostat is identified as a potential candidate for COVID-19 patients by scientists at the University of Tokyo and Leibniz…
Sun Pharma posts Q3FY20 gross sales at Rs 8,039 crores
In Q3, the company registered a net profit of Rs 914 crores
Sun Pharmaceutical Industries reported financials for the third…
Sun Pharma Announces Licensing Agreement With CSIR-IICT
This collaboration with CSIR-IICT for developing new drugs is part of our broader strategy for enhancing our global specialty…
Sun Pharma announces positive results of two phase-III CTs of Tildrakizumab
The IL-23p19 Therapeutic Antibody meets primary endpoints in both placebo-controlled studies and secondary endpoint in…
‘DRILS Synergy 2015’ symposium organised
The programme saw industry leaders and academia under one roof to discuss opportunities to build a culture of innovation and…